CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue	$ 10,338	$ 0	$ 10,338	$ 320
Operating expenses:
Research and development	27,366	20,856	49,686	32,305
General and administrative	4,025	3,242	7,352	6,401
Total operating expenses	31,391	24,098	57,038	38,706
Loss from operations	(21,053)	(24,098)	(46,700)	(38,386)
Other income (expense):
Loss from remeasurement of development derivative liability	(5,777)	(3,708)	(7,203)	(4,162)
Interest income	5	21	7	232
Interest expense	(254)	(379)	(539)	(757)
Foreign exchange gain (loss)	0	22	(2)	26
Total other expense	(6,026)	(4,044)	(7,737)	(4,661)
Net loss before income taxes	(27,079)	(28,142)	(54,437)	(43,047)
Provision for income taxes	1,600	0	1,600	0
Net loss	$ (28,679)	$ (28,142)	$ (56,037)	$ (43,047)
Net loss per common share, basic (in usd per share)	$ (0.60)	$ (0.98)	$ (1.41)	$ (1.50)
Net loss per common share, diluted (in usd per share)	$ (0.60)	$ (0.98)	$ (1.41)	$ (1.50)
Weighted average common shares outstanding, basic (in shares)	47,985,871	28,805,238	39,680,408	28,789,256
Weighted average common shares outstanding, diluted (in shares)	47,985,871	28,805,238	39,680,408	28,789,256
Sublicense revenue
Revenue	$ 10,338	$ 0	$ 10,338	$ 0
Grant revenue
Revenue	$ 0	$ 0	$ 0	$ 320